Genetic Technologies Limited Announces Expansion of Genetic Risk Assessment Tests and October Launch of New Breast Cancer and...
July 16 2018 - 5:30AM
Genetic Technologies Limited (ASX:GTG) (Nasdaq:GENE) (“Company”), a
diversified molecular diagnostics company embracing blockchain
technologies across genomic testing platforms, announced today that
both its new breast cancer and colorectal cancer risk assessment
tests are on track for release in October 2018. In addition
the company has already commenced development of other cancer and
disease targets for its predictive technologies. The company
expects to have the following tests available over the next 12
months:
- Prostate Cancer
- Melanoma
- Type 2 Diabetes
- Cardiovascular Disease
For perspective, there are 17.7 million deaths
per annum due to cardiovascular disease, 8.2 million deaths per
annum due to cancer and 1.6 million deaths per annum due to
diabetes. (Source: World Health Organisation).
Genetic Technologies Chairman and CEO, Dr Paul
Kasian commented: “This is a very exciting time for GTG. We are now
offering an opportunity for doctors to improve their ability to
assess a patient’s breast cancer risk. Our new test, when combined
with BRCA testing, will account for almost 100% of breast cancers.
Currently BRCA testing alone only accounts for 5 to 10% of breast
cancers. Added to this our expanded range of tests will allow
doctors to assess a patient’s risk to some of the most common
causes of morbidity and mortality.”
FOR FURTHER INFORMATION PLEASE CONTACT
Dr Paul KasianDirector & Interim CEOGenetic
Technologies Limited+ 61 3 8412 7000
Jason Wong (USA)Blueprint Life Science Group+1
(415) 375 3340, Ext. 4
About Genetic Technologies
Limited
Genetic Technologies is a diversified molecular
diagnostics company embracing blockchain technologies across
genomic testing platforms. GTG offers cancer predictive testing and
assessment tools to help physicians proactively manage patient
health. The Company’s lead product, BREVAGenplus®, is a clinically
validated risk assessment test for non-hereditary breast cancer and
is first in its class. For more information, please visit
www.brevagenplus.com and www.phenogensciences.com.
Genetic Technologies is developing a pipeline of
risk assessment products including a novel colorectal cancer (CRC)
test. For more information, please visit www.gtgcorporate.com
Safe Harbor Statement
Any statements in this press release that relate
to the Company's expectations are forward-looking statements,
within the meaning of the Private Securities Litigation Reform Act.
The Private Securities Litigation Reform Act of 1995 (PSLRA)
implemented several significant substantive changes affecting
certain cases brought under the federal securities laws, including
changes related to pleading, discovery, liability, class
representation and awards fees. Since this information may involve
risks and uncertainties and are subject to change at any time, the
Company's actual results may differ materially from expected
results. Additional risks associated with Genetic Technologies'
business can be found in its periodic filings with the SEC.
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Apr 2023 to Apr 2024